Everest Medicines Limited announced that it has entered into an agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences, to acquire exclusive rights to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain other Asian markets. VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, intended for the treatment of wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The agreement allows Everest Medicines to expand into the ophthalmology therapeutic area. The transaction does not constitute a disclosable transaction under the Hong Kong Stock Exchange listing rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.